1031394-22-5

Upstream product

• 1031400-93-7 1-(benzyloxy)-4-(1,1,1,3,3,3-hexafluoro-2-(methoxymethoxy)propan-2-yl)-2-n-propylbenzene 
• 150242-78-7 methyl 4-(benzyloxy)-3-n-propylbenzoate 
• 1031393-25-5 4-(1,1,1,3,3,3-hexafluoro-2-(methoxymethoxy)propan-2-yl)-2-n-propylphenol 
• 105211-78-7 methyl 4-hydroxy-3-n-propylbenzoate 
• 53596-60-4 methyl 3-allyl-4-hydroxybenzoate 
• 35750-24-4 methyl 4-allyloxybenzoate 
• 150242-80-1 C₁₇H₁₇ClO₂ 
• 2642-63-9 3',4'-dichloroacetophenone 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 95-50-1 1,2-dichloro-benzene 
• 1031401-04-3 1-(4-bromobutoxy)-4-(1,1,1,3,3,3-hexafluoro-2-(methoxymethoxy)propan-2-yl)-2-n-propylbenzene 
• 52715-58-9 5-(3,4-dichloro-phenyl)-5-methyl-imidazolidine-2,4-dione 

Relevant academic research and scientific papers

Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptor β-selective agonists

A novel series of 1,3-bistrifluoromethylcarbinol derivatives that act as liver X receptor (LXR) β-selective agonists was discovered. Structure-activity relationship studies led to the identification of molecule 62, which was more effective (Emax) and selective toward LXRβ than T0901317 and GW3965. Furthermore, 62 decreased LDL-C without elevating the plasma TG level and significantly suppressed the lipid-accumulation area in the aortic arch in a Bio F1B hamster fed a diet high in fat and cholesterol. We demonstrated that our LXRβ agonist would be potentially useful as a hypolipidemic and anti-atherosclerotic agent. In this manuscript, we report the design, synthesis and pharmacology of 1,3-bistrifluoromethylcarbinol derivatives.